Physician profile
Laura E Alexander
NPI 1780881128
$2,319.21
in general payments reported to CMS, 2019-2025
28 companies · $53.62 in 2025
The $53.62 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $91.46 · 2021: $153 · 2022: $254 · 2023: $527 · 2024: $701 · 2025: $53.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $511.82 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $404.18 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $331.61 | 2019-2024 | Vraylar, Viberzi, Linzess |
| Astellas Pharma US INC | $157.32 | 2019-2021 | |
| Lilly USA, LLC | $124.16 | 2023-2024 | Jardiance |
| Electromed, INC. | $118.37 | 2022-2024 | Smartvest |
| Xeris Pharmaceuticals, INC. | $92.89 | 2022-2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $49.15 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $42.58 | 2019-2024 | |
| Daiichi Sankyo INC. | $38.42 | 2021-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $38.19 | 2024 | |
| Shield Therapeutics INC | $36.85 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.77 | 2021-2022 | |
| Lundbeck LLC | $33.08 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $32.61 | 2023 | Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $32.59 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Allergan, INC. | $30.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $29.42 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $23.89 | 2019-2021 | |
| Ardelyx, INC. | $21.82 | 2024 | Ibsrela |
| Mylan Specialty L.P. | $21.29 | 2023 | Yupelri |
| Abbott Laboratories | $20.91 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.19 | 2019 | |
| Medtronic, INC. | $17.46 | 2022 | |
| Endo Pharmaceuticals INC. | $14.97 | 2020 | |
| Athena Bioscience, LLC | $14.45 | 2024 | Nexiclon Xr |
| Sanofi-Aventis U.S. LLC | $13.40 | 2023 | |
| Amarin Pharma, INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.